Jyoti Palaniappan - 17 Jun 2021 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role
SVP, Diagnostics, T-Detect
Signature
/s/ Jyoti Palaniappan by Eric Billings as attorney-in-fact
Issuer symbol
ADPT
Transactions as of
17 Jun 2021
Net transactions value
-$33,802
Form type
4
Filing time
21 Jun 2021, 20:00:20 UTC
Previous filing
19 May 2021
Next filing
19 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Options Exercise $14,680 +651 +7.1% $22.55 9,809 17 Jun 2021 Direct F1
transaction ADPT Common Stock Sale $26,040 -651 -6.6% $40.00* 9,158 17 Jun 2021 Direct F1
transaction ADPT Common Stock Options Exercise $29,338 +1,301 +14% $22.55 10,459 18 Jun 2021 Direct F1
transaction ADPT Common Stock Sale $51,780 -1,301 -12% $39.80* 9,158 18 Jun 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADPT Stock Option (Right to Buy) Options Exercise $0 -651 -0.61% $0.000000 106,345 17 Jun 2021 Common Stock 651 $22.55 Direct F1, F3
transaction ADPT Stock Option (Right to Buy) Options Exercise $0 -1,301 -1.2% $0.000000 105,344 18 Jun 2021 Common Stock 1,301 $22.55 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.
F2 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.59 to 40.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.